JP2020512002A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512002A5 JP2020512002A5 JP2019553899A JP2019553899A JP2020512002A5 JP 2020512002 A5 JP2020512002 A5 JP 2020512002A5 JP 2019553899 A JP2019553899 A JP 2019553899A JP 2019553899 A JP2019553899 A JP 2019553899A JP 2020512002 A5 JP2020512002 A5 JP 2020512002A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- cancer
- alkyl
- stem cells
- nme7
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000130 stem cell Anatomy 0.000 claims 39
- 108090000623 proteins and genes Proteins 0.000 claims 29
- 206010028980 Neoplasm Diseases 0.000 claims 22
- 201000011510 cancer Diseases 0.000 claims 22
- -1 methyl carboxy, ethyl carboxy, methoxy, ethoxy Chemical group 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 14
- 229940079593 drug Drugs 0.000 claims 14
- 229910052760 oxygen Inorganic materials 0.000 claims 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 13
- 230000001105 regulatory effect Effects 0.000 claims 12
- 229910052717 sulfur Inorganic materials 0.000 claims 11
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 230000000694 effects Effects 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 125000006413 ring segment Chemical group 0.000 claims 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 8
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 8
- 102100034256 Mucin-1 Human genes 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 101001128732 Homo sapiens Nucleoside diphosphate kinase 7 Proteins 0.000 claims 7
- 102100032115 Nucleoside diphosphate kinase 7 Human genes 0.000 claims 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 7
- 210000002950 fibroblast Anatomy 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 6
- 239000000556 agonist Substances 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 206010027476 Metastases Diseases 0.000 claims 4
- 208000007502 anemia Diseases 0.000 claims 4
- 230000009401 metastasis Effects 0.000 claims 4
- 208000037819 metastatic cancer Diseases 0.000 claims 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 3
- 108700028369 Alleles Proteins 0.000 claims 3
- 230000001093 anti-cancer Effects 0.000 claims 3
- 230000002001 anti-metastasis Effects 0.000 claims 3
- 230000024245 cell differentiation Effects 0.000 claims 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 150000002431 hydrogen Chemical group 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 230000035755 proliferation Effects 0.000 claims 3
- 208000026872 Addison Disease Diseases 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 208000003807 Graves Disease Diseases 0.000 claims 2
- 208000015023 Graves' disease Diseases 0.000 claims 2
- 208000001204 Hashimoto Disease Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 2
- 108700011259 MicroRNAs Proteins 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000005907 cancer growth Effects 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 231100000321 erythema Toxicity 0.000 claims 2
- 201000005298 gastrointestinal allergy Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000009545 invasion Effects 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 230000003278 mimic effect Effects 0.000 claims 2
- 208000012268 mitochondrial disease Diseases 0.000 claims 2
- 231100000065 noncytotoxic Toxicity 0.000 claims 2
- 230000002020 noncytotoxic effect Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 208000005987 polymyositis Diseases 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
- 208000025494 Aortic disease Diseases 0.000 claims 1
- 200000000007 Arterial disease Diseases 0.000 claims 1
- 102100035683 Axin-2 Human genes 0.000 claims 1
- 102000015735 Beta-catenin Human genes 0.000 claims 1
- 108060000903 Beta-catenin Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 101150107922 EEF1A1 gene Proteins 0.000 claims 1
- 102100029055 Exostosin-1 Human genes 0.000 claims 1
- 102000013339 FBXL17 Human genes 0.000 claims 1
- 101150000662 FBXL17 gene Proteins 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 102100032610 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Human genes 0.000 claims 1
- 101000874569 Homo sapiens Axin-2 Proteins 0.000 claims 1
- 101000918311 Homo sapiens Exostosin-1 Proteins 0.000 claims 1
- 101001014590 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Proteins 0.000 claims 1
- 101001014594 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Proteins 0.000 claims 1
- 101001014610 Homo sapiens Neuroendocrine secretory protein 55 Proteins 0.000 claims 1
- 101000797903 Homo sapiens Protein ALEX Proteins 0.000 claims 1
- 101000581118 Homo sapiens Rho-related GTP-binding protein RhoC Proteins 0.000 claims 1
- 101000843569 Homo sapiens Transcription factor HES-3 Proteins 0.000 claims 1
- 101000666934 Homo sapiens Very low-density lipoprotein receptor Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 101150114927 MUC1 gene Proteins 0.000 claims 1
- 102000007530 Neurofibromin 1 Human genes 0.000 claims 1
- 108010085793 Neurofibromin 1 Proteins 0.000 claims 1
- 101150051466 Nme7 gene Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 102100027610 Rho-related GTP-binding protein RhoC Human genes 0.000 claims 1
- 102100030773 Transcription factor HES-3 Human genes 0.000 claims 1
- 102100039066 Very low-density lipoprotein receptor Human genes 0.000 claims 1
- 102000013127 Vimentin Human genes 0.000 claims 1
- 108010065472 Vimentin Proteins 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000009509 drug development Methods 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 208000002741 leukoplakia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 229930014626 natural product Natural products 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000004738 parenchymal cell Anatomy 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 210000005048 vimentin Anatomy 0.000 claims 1
- 0 *CCCC(*=C)C(C1CCCCC1)=O Chemical compound *CCCC(*=C)C(C1CCCCC1)=O 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023190321A JP2024023246A (ja) | 2017-03-29 | 2023-11-07 | 幹細胞を分化し、癌を処置するための作用薬 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762478382P | 2017-03-29 | 2017-03-29 | |
| US62/478,382 | 2017-03-29 | ||
| US201762607880P | 2017-12-19 | 2017-12-19 | |
| US62/607,880 | 2017-12-19 | ||
| PCT/US2018/025107 WO2018183654A1 (en) | 2017-03-29 | 2018-03-29 | Agents for differentiating stem cells and treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023190321A Division JP2024023246A (ja) | 2017-03-29 | 2023-11-07 | 幹細胞を分化し、癌を処置するための作用薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020512002A JP2020512002A (ja) | 2020-04-23 |
| JP2020512002A5 true JP2020512002A5 (enExample) | 2021-01-14 |
| JP7383483B2 JP7383483B2 (ja) | 2023-11-20 |
Family
ID=63676977
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553899A Active JP7383483B2 (ja) | 2017-03-29 | 2018-03-29 | 幹細胞を分化し、癌を処置するための作用薬 |
| JP2023190321A Pending JP2024023246A (ja) | 2017-03-29 | 2023-11-07 | 幹細胞を分化し、癌を処置するための作用薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023190321A Pending JP2024023246A (ja) | 2017-03-29 | 2023-11-07 | 幹細胞を分化し、癌を処置するための作用薬 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20210087143A1 (enExample) |
| EP (1) | EP3600451B1 (enExample) |
| JP (2) | JP7383483B2 (enExample) |
| CN (1) | CN110799652A (enExample) |
| AU (1) | AU2018244449B2 (enExample) |
| CA (1) | CA3058190A1 (enExample) |
| IL (3) | IL302144A (enExample) |
| WO (1) | WO2018183654A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210087143A1 (en) | 2017-03-29 | 2021-03-25 | Minerva Biotechnologies Corporation | Agents for differentiating stem cells and treating cancer |
| US20210299109A1 (en) * | 2017-12-19 | 2021-09-30 | Minerva Biotechnologies Corporation | Agents for treating cancer and methods for identifying said agents |
| US20230227453A1 (en) * | 2020-06-10 | 2023-07-20 | Delix Therapeutics, Inc. | Tricyclic psychoplastogens and uses thereof |
| US20230242678A1 (en) | 2020-06-26 | 2023-08-03 | Minerva Biotechnologies Corporation | Anti-nme antibody and method of treating cancer or cancer metastasis |
| IL316221A (en) | 2022-04-12 | 2024-12-01 | Minerva Biotechnologies Corp | Anti-MUC1* variant antibodies and their uses |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3153015B2 (ja) * | 1992-09-07 | 2001-04-03 | サントリー株式会社 | ４−（アミノメチル）シクロヘキサンカルボキサミド誘導体 |
| CA2166975C (en) | 1993-07-16 | 2005-04-05 | Mark G. Bock | Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists |
| JP2003524598A (ja) * | 1998-09-04 | 2003-08-19 | アルタナ ファルマ アクチエンゲゼルシャフト | 新規ピラノセン |
| EP1158982A4 (en) * | 1999-03-03 | 2002-06-12 | Merck & Co Inc | Prenyl protein transferase inhibitors |
| JP2003509417A (ja) | 1999-09-14 | 2003-03-11 | アルタナ ファルマ アクチエンゲゼルシャフト | トリプターゼインヒビター |
| ATE269313T1 (de) * | 1999-12-20 | 2004-07-15 | Altana Pharma Ag | Tryptase-inhibitoren |
| TW200418835A (en) * | 2003-01-24 | 2004-10-01 | Tanabe Seiyaku Co | A pyrazolopyrimidine compound and a process for preparing the same |
| CN101115726A (zh) * | 2004-12-03 | 2008-01-30 | 先灵公司 | 作为cb1拮抗剂的取代哌嗪 |
| US8178317B2 (en) * | 2007-05-01 | 2012-05-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identifying transforming and tumor suppressor genes |
| CA2689945A1 (en) * | 2007-06-26 | 2008-12-31 | Astrazeneca Ab | 1-cyanocyclopropyl-derivatives as cathepsin k inhibitors |
| WO2009042815A1 (en) | 2007-09-25 | 2009-04-02 | Minerva Biotechnologies Corp. | Methods for treatment of cancer |
| USRE49686E1 (en) * | 2008-09-19 | 2023-10-10 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound and use of same |
| EP2582399A4 (en) * | 2010-06-16 | 2015-04-15 | Minerva Biotechnologies Corp | NEW PROGRAMMING OF CANCER CELLS |
| JP6220786B2 (ja) * | 2012-07-19 | 2017-10-25 | 大日本住友製薬株式会社 | １−（シクロアルキルカルボニル）プロリン誘導体 |
| EP2906541B1 (en) * | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| JP6640086B2 (ja) * | 2013-08-12 | 2020-02-05 | ミネルバ バイオテクノロジーズ コーポレーション | 腫瘍成長を増強する方法 |
| KR20160107322A (ko) * | 2014-01-14 | 2016-09-13 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 축합 ５－옥사졸리디논 유도체 |
| SG11201608389RA (en) * | 2014-04-07 | 2016-11-29 | Minerva Biotechnologies Corp | Anti-nme antibody |
| CN108513537A (zh) * | 2015-09-23 | 2018-09-07 | 米纳瓦生物技术公司 | 筛选分化干细胞的试剂的方法 |
| US20210087143A1 (en) * | 2017-03-29 | 2021-03-25 | Minerva Biotechnologies Corporation | Agents for differentiating stem cells and treating cancer |
| US20210299109A1 (en) * | 2017-12-19 | 2021-09-30 | Minerva Biotechnologies Corporation | Agents for treating cancer and methods for identifying said agents |
-
2018
- 2018-03-29 US US16/498,640 patent/US20210087143A1/en not_active Abandoned
- 2018-03-29 EP EP18777506.9A patent/EP3600451B1/en active Active
- 2018-03-29 CN CN201880036852.2A patent/CN110799652A/zh active Pending
- 2018-03-29 JP JP2019553899A patent/JP7383483B2/ja active Active
- 2018-03-29 WO PCT/US2018/025107 patent/WO2018183654A1/en not_active Ceased
- 2018-03-29 IL IL302144A patent/IL302144A/en unknown
- 2018-03-29 AU AU2018244449A patent/AU2018244449B2/en active Active
- 2018-03-29 CA CA3058190A patent/CA3058190A1/en active Pending
-
2019
- 2019-09-25 IL IL26966519A patent/IL269665A/en unknown
-
2021
- 2021-10-28 US US17/512,978 patent/US12202799B2/en active Active
-
2022
- 2022-02-22 IL IL290810A patent/IL290810A/en unknown
-
2023
- 2023-11-07 JP JP2023190321A patent/JP2024023246A/ja active Pending
-
2024
- 2024-06-26 US US18/755,447 patent/US20240409515A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020512002A5 (enExample) | ||
| Hockla et al. | PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer | |
| Liu et al. | FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells | |
| Jokilehto et al. | Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness. | |
| Janky et al. | Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma | |
| Sicklick et al. | Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis | |
| Armah et al. | Epithelioid sarcoma | |
| Ferrer et al. | Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells | |
| Mikhail et al. | PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation | |
| Edgar et al. | Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors | |
| Einarsdottir et al. | Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions | |
| Timofeeva et al. | Conditionally reprogrammed normal and primary tumor prostate epithelial cells: a novel patient-derived cell model for studies of human prostate cancer | |
| Dong et al. | ADAM9 mediates the interleukin-6-induced Epithelial–Mesenchymal transition and metastasis through ROS production in hepatoma cells | |
| Pobbati et al. | Identification of quinolinols as activators of TEAD-dependent transcription | |
| Gao et al. | Association of E-cadherin, matrix metalloproteinases, and tissue inhibitors of metalloproteinases with the progression and metastasis of hepatocellular carcinoma | |
| Gauglhofer et al. | Fibroblast growth factor receptor 4: A putative key driver for the aggressive phenotype of hepatocellular carcinoma | |
| Chen et al. | Interaction between macrophage extracellular traps and colon cancer cells promotes colon cancer invasion and correlates with unfavorable prognosis | |
| Lee et al. | The promise and peril of chemical probe negative controls | |
| Sakharpe et al. | Epithelioid sarcoma and unclassified sarcoma with epithelioid features: clinicopathological variables, molecular markers, and a new experimental model | |
| JP2024023246A5 (enExample) | ||
| Chen et al. | Genetic alterations and expression of PTEN and its relationship with cancer stem cell markers to investigate pathogenesis and to evaluate prognosis in hepatocellular carcinoma | |
| Galli et al. | Neuropeptide Y as a biomarker and therapeutic target for neuroblastoma | |
| Puxeddu et al. | Induction of ferroptosis in glioblastoma and ovarian cancers by a new pyrrole tubulin assembly inhibitor | |
| Ferician et al. | Endostatin effects on tumor cells and vascular network of human renal cell carcinoma implanted on chick embryo chorioallantoic membrane | |
| Zhang et al. | High ADAM8 expression is associated with poor prognosis in patients with hepatocellular carcinoma |